Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
sector : Professional, scientific, and technical services entities : Synaptogenix inc save search
Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative Disorders
Published: 2023-12-19 (Crawled : 14:30) - biospace.com/
SNPX | $4.66 -2.92% -3.0% 42K
|
Professional, Scientific, and T...
|
| O: 5.42%
H: 3.45%
C: 0.03%
presentation disorders neurodegenerative
Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Disease
Published: 2023-09-26 (Crawled : 14:00) - biospace.com/
SNPX | $4.66 -2.92% -3.0% 42K
|
Professional, Scientific, and T...
|
| O: 5.64%
H: 5.26%
C: 0.03%
disease publication alzheimer's trial results benefits
Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study
Published: 2023-09-07 (Crawled : 13:00) - prnewswire.com
SNPX | $4.66 -2.92% -3.0% 42K
|
Professional, Scientific, and T...
|
| O: 9.31%
H: 5.47%
C: -19.7%
pre-clinical als treatment results study
Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis
Published: 2023-07-19 (Crawled : 14:20) - biospace.com/
SNPX | $4.66 -2.92% -3.0% 42K
|
Professional, Scientific, and T...
|
| O: 3.4%
H: 2.13%
C: -6.38%
fda drug sclerosis application trial
Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neuroscience
Published: 2023-07-13 (Crawled : 14:00) - biospace.com/
SNPX | $4.66 -2.92% -3.0% 42K
|
Professional, Scientific, and T...
|
| O: 16.14%
H: 88.0%
C: 4.0%
disease world presentation international research alzheimer's benefits
Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease
Published: 2022-12-16 (Crawled : 17:00) - biospace.com/
SNPX | $4.66 -2.92% -3.0% 42K
|
Professional, Scientific, and T...
|
| O: -64.69%
H: 4.79%
C: -28.14%
disease alzheimer's topline trial phase 2
Synaptogenix Welcomes Lecanemab Phase 3 Trial Results
Published: 2022-09-28 (Crawled : 16:00) - prnewswire.com
SNPX | $4.66 -2.92% -3.0% 42K
|
Professional, Scientific, and T...
|
| O: 6.97%
H: 0.0%
C: -6.92%
trial results lecanemab
Synaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News Network
Published: 2022-08-12 (Crawled : 13:20) - prnewswire.com
SNPX | $4.66 -2.92% -3.0% 42K
|
Professional, Scientific, and T...
|
| O: -1.42%
H: 8.76%
C: 6.61%
Synaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data
Published: 2022-07-26 (Crawled : 16:00) - biospace.com/
SNPX | $4.66 -2.92% -3.0% 42K
|
Professional, Scientific, and T...
|
| O: 2.05%
H: 8.08%
C: 4.23%
phase 2
Synaptogenix Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer's Disease Trial Data
Published: 2022-07-20 (Crawled : 14:00) - biospace.com/
SNPX | $4.66 -2.92% -3.0% 42K
|
Professional, Scientific, and T...
|
| O: 0.65%
H: 11.11%
C: 5.13%
disease alzheimer's trial phase 2
Synaptogenix Completes Patient Enrollment in NIH Sponsored Phase 2b Alzheimer's Disease Trial
Published: 2022-04-19 (Crawled : 13:20) - prnewswire.com
SNPX | $4.66 -2.92% -3.0% 42K
|
Professional, Scientific, and T...
|
| O: 2.92%
H: 0.0%
C: -8.37%
disease trial alzheimer's enroll alzheimer’s phase 2b
New Peer Reviewed Article Demonstrates Extended Therapeutic Potential of Synaptogenix's Bryostatin for Alzheimer's Disease
Published: 2022-04-05 (Crawled : 13:20) - prnewswire.com
SNPX | $4.66 -2.92% -3.0% 42K
|
Professional, Scientific, and T...
|
| O: 3.42%
H: 4.77%
C: -1.85%
disease potential bryostatin alzheimer's disease alzheimer's alzheimer’s
Synaptogenix to Present at Hanson Wade 10th Annual Neurodegenerative Drug Development Summit
Published: 2022-03-29 (Crawled : 19:00) - biospace.com/
SNPX | $4.66 -2.92% -3.0% 42K
|
Professional, Scientific, and T...
|
| O: 0.14%
H: 5.64%
C: 3.53%
drug neurodegenerative
Synaptogenix to Present at Sachs 5th Annual Neuroscience Innovation Forum
Published: 2022-03-22 (Crawled : 14:00) - biospace.com/
SNPX | $4.66 -2.92% -3.0% 42K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 3.2%
C: 0.0%
Synaptogenix to Present Research Highlighting Potential Broad Applicability for Lead Compound Bryostatin at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)
Published: 2022-03-15 (Crawled : 13:30) - prnewswire.com
SNPX | $4.66 -2.92% -3.0% 42K
|
Professional, Scientific, and T...
|
| O: 0.92%
H: 7.12%
C: -2.15%
alzheimer parkinson research conference disease potential international tiona alzheimer’s bryostatin alzheimer's
Synaptogenix Moves Forward with Clinical Development Plans for Bryostatin-1 as a Treatment for Multiple Sclerosis
Published: 2022-02-23 (Crawled : 18:00) - biospace.com/
SNPX | $4.66 -2.92% -3.0% 42K
|
Professional, Scientific, and T...
|
| O: 0.94%
H: 8.04%
C: 3.87%
multiple sclerosis treatment sclerosis bryostatin
Synaptogenix Announces Publication of Peer-Reviewed Scientific Article Evidencing Byrostatin-1's Improved Cognition Over Baseline in Advanced Alzheimer's Disease Patients
Published: 2022-02-01 (Crawled : 15:00) - biospace.com/
SNPX | $4.66 -2.92% -3.0% 42K
|
Professional, Scientific, and T...
|
| O: 5.13%
H: 29.88%
C: 23.05%
alzheimer disease alzheimer’s alzheimer's disease bryostatin alzheimer's
Synaptogenix Announces Participation at the Benzinga Healthcare Small Cap Conference
Published: 2021-09-28 (Crawled : 14:15) - biospace.com/
SNPX | $4.66 -2.92% -3.0% 42K
|
Professional, Scientific, and T...
|
| O: -0.51%
H: 0.0%
C: -2.89%
conference
Synaptogenix Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference
Published: 2021-09-10 (Crawled : 13:15) - prnewswire.com
SNPX | $4.66 -2.92% -3.0% 42K
|
Professional, Scientific, and T...
|
| O: 1.93%
H: 0.44%
C: -1.17%
conference
Synaptogenix Signs Memorandum Of Understanding with Nemours A.I. DuPont Hospital to Initiate Trial Using Bryostatin, Under Orphan Drug Status, to Treat Fragile X Syndrome
Published: 2021-08-05 (Crawled : 16:00) - biospace.com/
SNPX | $4.66 -2.92% -3.0% 42K
|
Professional, Scientific, and T...
|
| O: 0.92%
H: 4.82%
C: -7.04%
drug trial syndros bryostatin
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.